Xencor Inc XNCR

Healthcare Biotechnology

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

NDAQ:XNCR - Post by User

Xencor Inc

<< Previous

Bullboard Posts

(301)
•••

Post by whytestockson Dec 02, 2024 2:46pm

39 Views

Post# 36341243

Overweight Recommendation Issued On XNCR By Piper Sandler

Just In: $XNCR Overweight Recommendation Issued On XNCR By Piper Sandler2024-12-02 05:15:02 ET Piper Sandler analyst issues OVERWEIGHT recommendation for XNCR on December 2, 2024 08:43AM ET. XNCR was trading at $25.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Strong ...XNCR - Overweight Recommendation Issued On XNCR By Piper Sandler

<< Previous

Bullboard Posts

Anaergia signs $25M biomethane deal in Italy